RAPID ALERT

DRAP ALERT NO. Nº II/S/06-23-28

FALSIFIED CIPROXIN 500MG TABLETS

Date: 19th June 2023

Target Audience:

- Regulatory Field Force.
- Healthcare Professionals - Physicians, Pharmacists, and Nurses.
- General Public.

Problem Statement:

Provincial Drug Control team has seized suspected falsified **Ciproxin 500mg Tablets** during the market surveillance activities in the District Kasur, Punjab. The Manufacturing Authorization holder company i.e. M/s Bayer Pakistan (Pvt) Ltd, Karachi has stated that based on the physical verification of security features, the products seized are not genuine, and thus it is a spurious/falsified products.

The product detail is as under: -

Product Name	Composition	Batch No.	Manufactured by	Remarks
	(As stated on the label)			
Ciproxin 500mg Tablets Mfg.Date: 12-21 Exp.Date: 11-26	Ciprofloxacin	BAA928	Novartis Pharma (Pakistan) Ltd, Karachi *For* Bayer Pakistan (Pvt) Ltd, Lahore	The manufacturing company has stated that these products are not manufactured by them.

Risk Statement:

Consequences of the use of Spurious/ Falsified Drugs include but are not limited to the followings:

- Falsified/Spurious drugs may contain toxic and narcotic/psychotropic ingredients in unacceptable doses which may be life-threatening.
- These are manufactured under unhygienic conditions without the proper inspection and approval, which are highly injurious to human health.
- Poor-quality medicines compromise the treatment of diseases and may intensify the existing condition.

DRAP, Islamabad

92 51 9107404

gsms@dra.gov.pk

Action Initiated: -

The Regulatory Field Force has been directed to increase surveillance throughout the supply chain to confiscate these products. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should **immediately check** the stock, and information related to the supplier of such products should be provided to the Regulatory field force (DRAP, Provincial Health Departments and States) to ensure the removal of this product.

Advice for Healthcare Professionals: -

DRAP requests increased vigilance at hospitals and within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this product.

Adverse reactions or quality problems experienced with the use of this product shall be reported to the National Pharmacovigilance Centre(NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.

Advice for Consumers / General public: -

Consumers should not use this product and shall contact their physician or healthcare provider if they have experienced any problem related to taking or using this drug product, and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

Drug Regulatory Authority of Pakistan
محفوظ، موثر اور معیاری اشیائے علاج

DRAP, Islamabad
92 51 9107404
gsms@dra.gov.pk